---
last_updated: 2026-06-03
total_topics: 46
---

# Health Knowledge Base Index

The cloud document (SSOT) lives at `~/health/cloud-doc.md` - always fetch fresh from there for current values.

## Topics by Priority

### URGENT

| Topic | File | Last Updated | Key Coverage | Open Questions |
|---|---|---|---|---|
| **Whole-Profile Seriousness Triage** | [whole-profile-seriousness-triage.md](topics/whole-profile-seriousness-triage.md) | 2026-06-03 | Forest-before-trees hierarchy: red-flag overrides, very high Lp(a) plus newly recovered 2024 mild right-leg PAD/peripheral plaque record, stool-blood/iron branch despite improved clean-month results, thrombocytosis/leukocytosis, bloating/spot-pain burden, historical hip OA/calcific-tendinitis context, and threat-monitoring boundaries | What do cardiac imaging, BP, repeat CBC/smear, and trigger-based stool/iron follow-up show? |
| **Lipoprotein(a)** | [lp-a.md](topics/lp-a.md) | 2026-06-03 | Stable anchor for Lp(a) 838.6 mg/L plus 2024 RPPH right common-femoral plaque/mild PAD finding: raw-unit handling, risk-modifier framing, ApoB/LDL/smoking/BP priorities, coronary/valve imaging rationale, PCSK9/ezetimibe discussion thresholds, and no self-directed aspirin while GI bleeding risk is live | What do CAC/CCTA/echo show beyond the documented peripheral plaque, and what target will cardiology use? Can future Lp(a) retesting use nmol/L? |
| **Prevention Status + CVD Burden** | [prevention-status-cvd-burden.md](topics/prevention-status-cvd-burden.md) | 2026-06-03 | Archived pointer updated after 2024 RPPH Doppler was found: profile is not risk-factor-only anymore, but coronary/valve staging and aspirin/PCSK9 decisions still belong in the Lp(a) master | What do baseline CAC/CCTA/echo show, and what target will cardiology use if plaque burden is broader? |
| **Recurrence Action Plan** | [recurrence-action-plan.md](topics/recurrence-action-plan.md) | 2026-04-27 | Practical rule for recurrence of the early-April 2025 pain episode: when to use ECG + high-sensitivity troponin / ER instead of GI speculation | Which Phnom Penh facility is the fastest reliable ECG/troponin route if symptoms recur? |
| **Diverticular Disease** | [diverticular-disease.md](topics/diverticular-disease.md) | 2026-05-30 | Fiber evidence, post-bleeding management, exercise, alcohol/smoking exposure framing, rebleeding risk, normalized calprotectin vs occult blood, private 2025-08-20 stool-photo comparator, high-quality 2024 colonoscopy, and the April 2026 stool-positive signal cooling after 2026-05-28 FOB negative/stool RBC absent | Does the 2026-05-28 negative repeat stool result hold if symptoms or iron drift recur? If persistence returns, which GI-source branch should clinician prioritize? |
| **Occult Stool Blood Workup** | [occult-stool-blood-workup.md](topics/occult-stool-blood-workup.md) | 2026-05-07 | FOB positive + stool RBC with normal calprotectin, FOB/FIT/direct-exam assay-quality audit, private 2025-08-20 visible-bleeding photo comparator, low-plausibility pre-bleed topical mupirocin exposure review, high-quality 2024 colonoscopy abstraction, repeat-stool rules, and lower-vs-upper/small-bowel escalation thresholds | Will repeat FOB/direct exam clear or persist? Can a reliable quantitative FIT be accessed locally? If occult blood persists despite high-quality 2024 colonoscopy, which source-localization branch should clinician prioritize? |
| **Bloating vs Bleeding Risk** | [bloating-vs-bleeding-risk.md](topics/bloating-vs-bleeding-risk.md) | 2026-04-29 | Router that separates symptom/fermentation branches from bleeding branches; states the boundary rule that SIBO/bloating does not explain positive FOB or stool RBCs | Which component of the current bloating pattern is SIBO/MMC vs SUDD vs food-load intolerance? Does repeat stool blood persist? |
| **Abdominal Spot-Pain Map** | [abdominal-spot-pain-map.md](topics/abdominal-spot-pain-map.md) | 2026-05-05 | Pain-location/duration router for brief migrating abdominal spot pains: separates gas/visceral-sensitivity/SIBO-SUDD-IBS overlap, diet-soda/carbonation triggers, persistent focal inflammatory pain, bleeding signals, and cardiac red flags | Do pains fade during the clean experiment, cluster with distension/meal timing/gas/stool/Coke Zero or carbonation, or persist with objective inflammatory/stool-blood signals? |

### IMPORTANT

| Topic | File | Last Updated | Key Coverage | Open Questions |
|---|---|---|---|---|
| **CT Scan Screening** | [ct-scan-screening.md](topics/ct-scan-screening.md) | 2026-05-08 | Sourced CT modality boundaries: CAC as the low-friction coronary anchor, CAC=0 limits in very high Lp(a), conditional CCTA/AI-QCT, LDCT pack-year criteria, abdomen CT triggers, full-body CT rejection, and 2026-05-08 RPPH coronary-CT route update with CTA Coronary/echo package caveats | Prior CAC history? Does RPPH provide standalone CAC, contrast CCTA, or both, and what plaque fields are reported? |
| **Lp(a) Therapy Watchlist** | [lpa-therapy-watchlist.md](topics/lpa-therapy-watchlist.md) | 2026-06-03 | Pelacarsen, olpasiran, lepodisiran, muvalaplin, zerlasiran, PCSK9 bridge logic, trial milestones, and Southeast Asia/Norway access check; 2024 mild PAD strengthens prevention intensity but does not create an approved Lp(a)-specific route | Will outcomes trials show event reduction, and will labels include mild PAD/peripheral plaque, coronary plaque, or only established major ASCVD? |
| **Smoking + Alcohol Relapse Risk** | [smoking-alcohol-relapse-risk.md](topics/smoking-alcohol-relapse-risk.md) | 2026-05-27 | Separates fixed Lp(a) from modifiable risk stacking; smoking as the highest-ROI risk amplifier; WBC/neutrophil correlation now treats late-2025 as exposure-confounded rather than smoke-free; alcohol-plus-smoking periods are framed as gut/iron-marker destabilizers, not proven direct bleeding causation | Can older CBC dates be accurately labeled smoking vs smoke-free, and do improved clean-month markers hold if abstinence continues? |
| **Daily Cannabis / Dry-Herb Vaping Risk** | [cannabis-daily-vaping-risk.md](topics/cannabis-daily-vaping-risk.md) | 2026-05-24 | Compares 20 g/week dry-herb cannabis vaping with pack/day cigarettes: lower combustion/cancer/COPD certainty than tobacco, but high daily THC exposure with dependence, sleep/cognition/mental-health, CHS, impairment, and cardiovascular-trigger concerns | If cannabis is ever tested later, can it stay non-daily, low-THC/high-CBD, dry-herb only, and outside BP/lab/imaging interpretation windows? |
| **Blood Pressure Profile** | [blood-pressure-profile.md](topics/blood-pressure-profile.md) | 2026-05-03 | Home BP/ABPM acquisition protocol, self-start rule, validated upper-arm cuff buying checklist, Grab Mart/UCare sourcing cautions, Tracker logging, and how BP changes cardiovascular risk management in high Lp(a) | What is the 7-day home BP average? Is there masked or morning hypertension? |
| **Aortic Valve + Vascular Aging** | [aortic-valve-vascular-aging.md](topics/aortic-valve-vascular-aging.md) | 2026-05-04 | Baseline echocardiography and valve-surveillance router for very high Lp(a), including CAC=0 boundaries, pulse pressure/BP variability, arterial-stiffness triage, and AS follow-up intervals by severity | What does baseline echo show, and what are the 7-day BP average and pulse pressure? |
| **Sleep Apnea + Nocturnal BP** | [sleep-apnea-nocturnal-hypoxia.md](topics/sleep-apnea-nocturnal-hypoxia.md) | 2026-05-03 | Trigger-based OSA/nocturnal-hypoxia router: STOP-BANG symptom check, Apple Watch breathing/SpO2 limits, morning BP/ABPM triggers, RPH HSAT/PSG route, and how confirmed OSA changes BP/autonomic-risk handling | Do home BP, symptoms, or repeated Apple Watch breathing/oxygen signals justify HSAT or sleep consultation? |
| **Longitudinal Cohort Risk Translation** | [longitudinal-cohort-risk-translation.md](topics/longitudinal-cohort-risk-translation.md) | 2026-06-03 | Cohort atlas translating Copenhagen/ERFC/US pooled/MESA/EPIC Lp(a) data, Framingham/British Doctors BP/smoking evidence, and diverticular cohorts into this profile; now explicitly accounts for the recovered 2024 mild PAD/peripheral-plaque record | Which personal risk branch changes once BP profile and CAC/echo/CCTA results are known? |
| **LDNCP & Advanced Imaging** | [ldncp-advanced-imaging.md](topics/ldncp-advanced-imaging.md) | 2026-06-03 | Compact CAC-vs-CCTA-vs-echo decision pathway for very high Lp(a), now starting from known 2024 mild peripheral plaque/PAD; covers non-calcified plaque blind spots, AI-QCT usefulness, symptom escalation, antiplatelet implications, and RPPH coronary-CT route caveats | Does RPPH CTA Coronary/CCTA include plaque characterization? What do CAC/CCTA/echo show beyond the prior right-leg Doppler? |
| **Antithrombotic Strategy** | [antithrombotic-strategy.md](topics/antithrombotic-strategy.md) | 2026-06-03 | Archived aspirin/antiplatelet pointer updated after 2024 mild PAD record: very high Lp(a) plus plaque makes aspirin tempting, but prior diverticular/stool-blood/iron history keeps it clinician-led only | Would coronary plaque/progressive PAD later create a clinician-led antiplatelet indication after GI risk review? |
| **Medication List + Hard Avoids** | [medication-avoid-list.md](topics/medication-avoid-list.md) | 2026-06-03 | Current-known medication/supplement safety anchor: 2026-05-04 confirms atorvastatin 20 mg, eczema cortisone cream for flare-ups, and no aspirin; 2024 RPPH papers preserve historical aspirin 81 + atorvastatin 40 + omeprazole after mild PAD Doppler; eye drops, sildenafil timing, and exact supplement products still need product-level confirmation | Which eye drops, topical steroid potency/site pattern, sildenafil timing, and exact supplement products/doses are current? |
| **SIBO & MMC** | [sibo-mmc.md](topics/sibo-mmc.md) | 2026-05-30 | Compact symptom-pathway framework for SIBO/MMC vs bile-acid diarrhea vs SUDD/diverticulitis, breath-test/BAD-test usefulness, broad microbiome-sequencing avoidance, Phnom Penh logistics, treatment caveats, meal-spacing experiment logic, final-week coffee-reduction/tea-substitution context, diet-soda/carbonation trigger logic, alcohol-plus-smoking as a personal gut destabilizer, and circumference/distension/stool-pattern tracking | Does meal spacing/no-snacking materially reduce bloating? Do tea-only days differ from coffee-exception days, or is a future clean no-coffee trial needed? Does Coke Zero/diet soda reproducibly trigger same-day ache/bloating? Do logs show watery urgency often enough to justify asking about bile-acid testing, or should that branch be dropped? |
| **Eczema-Diverticular Connection** | [eczema-diverticular-connection.md](topics/eczema-diverticular-connection.md) | 2026-05-04 | Evidence-tiered skin-gut and microbiome filter: fiber/plant diversity, optional fermented foods, one-probiotic-if-useful logic, plus rejection of broad microbiome sequencing, fecal SCFA panels, TMAO chasing, and histamine overreach | How much of the remaining inflammatory tone is skin/allergic rather than gut-driven now that calprotectin normalized? |

### IMPORTANT (ADDITIONAL)

| Topic | File | Last Updated | Key Coverage | Open Questions |
|---|---|---|---|---|
| **Thrombocytosis Workup Pathway** | [thrombocytosis-lpa-thrombosis.md](topics/thrombocytosis-lpa-thrombosis.md) | 2026-05-30 | Platelet-first workup pathway updated after clean-month results: WBC normalized to 7.7, platelets improved to 444 but remain borderline/high by lab range; reactive causes, cooled stool-blood/iron branch, smear triggers, JAK2 first, CALR/MPL next, BCR-ABL1 if smear/differential points myeloid, and CHIP as risk-framing only if a clone is found | Do platelets drop further below 450 or remain borderline/high on repeat, and do smear/molecular testing become necessary? If classic drivers are negative but counts persist, does hematology use broader myeloid/CHIP NGS or marrow morphology? |
| **Elevated IgA Workup** | [elevated-iga-workup.md](topics/elevated-iga-workup.md) | 2026-05-30 | IgA follow-up reweighted after IgA fell to 546.6 but remains high, IgG/IgM are normal, urine is clean, hemoglobin electrophoresis is normal, and 2026-05-28 true protein electrophoresis shows no obvious narrow M-spike with mildly high beta fractions | Does IgA continue falling or persist above range, and does clinician/lab review agree the SPEP pattern has no monoclonal band? |
| **Inflammatory-Thrombotic Axis** | [inflammatory-thrombotic-axis.md](topics/inflammatory-thrombotic-axis.md) | 2026-05-30 | ESR/CRP/fibrinogen/WBC/platelet cluster updated after clean-month end results: WBC normalized to 7.7, ferritin/TSAT improved, stool blood cleared, platelets improved to 444 but remain borderline/high by lab range, fibrinogen 3.9 high-normal; outcome-impact framing, exposure labeling, ranked intervention hierarchy, and dental/periodontal source-cleanup checklist | Do follow-up CBC/fibrinogen markers keep improving? Can older CBC dates be assigned accurate smoking-status labels? Does dental review show active periodontitis/infection if source-hunting remains needed? |
| **TSH Thyroid Trend** | [tsh-thyroid-trend.md](topics/tsh-thyroid-trend.md) | 2026-05-04 | Former TSH-creep concern, now reframed after normalization from 3.61 to 1.75; NICE NG145 added as the thyroid-testing anchor; statin-thyroid interaction kept as background rather than active alarm | Was the Dec 2025 rise transient, lab noise, or a real reversible signal? |
| **Calcium-PTH-Vitamin D Axis** | [calcium-parathyroid-vitamin-d.md](topics/calcium-parathyroid-vitamin-d.md) | 2026-05-03 | Guideline/source-anchored calcium/PTH/D router: stable high-normal total calcium, normalized PTH, sufficient 25(OH)D, same-day paired-axis recheck logic, Biomed tariff limits, and K2/Lp(a)-valve boundary | Can ionized calcium be accessed locally if total calcium crosses range or PTH rises? What does baseline echo show? |
| **HDL Cholesterol** | [hdl.md](topics/hdl.md) | 2026-04-23 | U-shaped CV risk, function vs quantity, HDL-Lp(a) interaction, and the downgraded concern after HDL backed off from 2.53 to 1.99 | Was the Dec 2025 peak just fluctuation, or does it still deserve follow-up if it returns? |
| **Omega-3 Supplementation** | [omega-3.md](topics/omega-3.md) | 2026-05-04 | Conservative maintenance-dose framing, krill-vs-fish equivalence, bleeding-risk context, and no current self-escalation indication | Would prescription EPA ever enter via cardiology/plaque/triglyceride logic? |
| **Vitamin D and K2** | [vitamin-d-k2.md](topics/vitamin-d-k2.md) | 2026-05-03 | D3 already sufficient; current NOW product is MK-4; D/K2 escalation is optional supplement hygiene, not proven Lp(a)-valve/CAC therapy | Is there any reason to change K2 form after the supplement stack is simplified? |
| **B12 / Functional Deficiency Follow-up** | [b12-functional-deficiency.md](topics/b12-functional-deficiency.md) | 2026-05-04 | Low-normal recurrent B12, vegetarian/brain-fog context, NICE NG239 decision tree, Biomed test availability, and clarified maintenance vs short repletion-trial dosing | Does homocysteine normalize with oral B12? Is MMA accessible locally if symptoms persist? |
| **Celiac + Autoimmune Gastritis + Malabsorption Screen** | [malabsorption-celiac-autoimmune-gastritis.md](topics/malabsorption-celiac-autoimmune-gastritis.md) | 2026-05-03 | Trigger-based malabsorption boundary: tTG-IgA while eating gluten if iron/diarrhea/weight-loss/bloating signals justify it; no broad autoimmune-gastritis panel unless B12/iron response or gastroscopy triggers it | Can Biomed arrange off-menu/send-out tTG-IgA, and do end-of-experiment trends justify screening now? |
| **Probiotics** | [probiotics.md](topics/probiotics.md) | 2026-05-04 | Low-certainty SUDD symptom evidence, modest adult-AD strain-specific signal, one-base-product logic, S. boulardii rare-risk boundary, and CBM588 adjunct framing | Does stopping daily S. boulardii worsen logged symptoms enough to keep it? |
| **Supplement Stack + Add-ons** | [recommended-supplement-adjustments.md](topics/recommended-supplement-adjustments.md) | 2026-05-08 | Single supplement hub: keep/conditional/defer/stop router across D3/K2, fish oil, probiotics, B12/B-complex, magnesium, zinc, psyllium, iron, quercetin, and turmeric+piperine; psyllium is low-priority when stool firmness is consistently good; turmeric+piperine stays stopped; avoid chronic high-dose B6. | Does daily S. boulardii earn its place after a stop trial? Does psyllium improve stool regularity/bloating logs without increasing distension if it is deliberately tested later? What exact B6 dose, if any, is in the current B-complex? |
| **Clostridium butyricum CBM588** | [clostridium-butyricum.md](topics/clostridium-butyricum.md) | 2026-05-04 | Exact-strain CBM588 symptom-trial framing, symptom-vs-flare distinction, anti-stacking rule, and Phnom Penh sourcing status | Incremental benefit on top of one base probiotic? Exact Phnom Penh stock? |
| **Apple Health Signal Mining** | [apple-health-signals.md](topics/apple-health-signals.md) | 2026-04-22 | Wearable signal interpretation for smoking, alcohol, gut-flare discrimination, iron-performance tracking limits, and home-monitoring priorities | Can standardized route efficiency expose iron-related drift early? Which anomaly clusters map to smoking vs alcohol vs illness? |

### MONITOR

| Topic | File | Last Updated | Key Coverage | Open Questions |
|---|---|---|---|---|
| **Ferritin & Iron Workup** | [ferritin-iron-workup.md](topics/ferritin-iron-workup.md) | 2026-05-30 | Iron-loss diagnosis updated after completed clean-month results: ferritin improved to 61.60 and TSAT 33.4 after midpoint ferritin 43.28/TSAT 27.7, with 2026-05-28 FOB negative/stool RBC absent; late-2025 ferritin decline is exposure-confounded with a negative next-day stool test, while April 2026 remains the prior stool-positive branch | Do ferritin/TSAT/Hb stay stable if alcohol/smoking abstinence continues, and does stool blood remain negative if repeated by trigger? |
| **Oral Iron Repletion Strategy** | [oral-iron-repletion.md](topics/oral-iron-repletion.md) | 2026-04-27 | Practical oral iron start/skip rules, alternate-day low-dose regimen, absorption timing, tolerance constraints, and response targets | Start now or wait for stool-blood and ferritin/TSAT trend? Which local product is best tolerated? |
| **PSA Kinetics** | [psa-kinetics.md](topics/psa-kinetics.md) | 2026-05-03 | AUA/SUO + EAU anchored repeat-test router: standardized PSA confirmation first, free PSA/DRE/risk-calculator/prostate-volume/PSA-density/urology/MRI only if the branch persists | Does standardized repeat PSA fall, stay near/above 3, or rise with concerning free-PSA/DRE/risk-calculator context? |

**Note:** the old standalone `blood-test-round-synthesis.md` draft was retired; its round-by-round narrative has been folded into the Blood Test Explorer date summaries in `report.html` so the research is still preserved.

### TEST PLANS

| Document | File | Last Updated | Coverage |
|---|---|---|---|
| **30-Day Experiment** | [thirty-day-experiment.md](topics/thirty-day-experiment.md) | 2026-05-30 | Completed 2026-04-26 14:00 -> 2026-05-26 14:00 Cambodia clean-month protocol: zero alcohol/smoking, Tracker logging, stool photos, Apple Watch capture, final-week coffee-reduction/tea-substitution attempt with logged coffee exceptions, midpoint 2026-05-12 blood checkpoint, 2026-05-27 blood improvement with ferritin 61.60/TSAT 33.4/WBC 7.7/platelets 444, and 2026-05-28 FOB negative/stool RBC absent. |
| **Post-30-Day Non-Invasive Examination Plan** | [post-30-day-noninvasive-exam-plan.md](topics/post-30-day-noninvasive-exam-plan.md) | 2026-06-03 | Post-experiment router updated after paired clean-month end results and recovered 2024 mild PAD record: keep alcohol/smoking avoidance, treat 2026-05-28 FOB negative/stool RBC absent as cooling the GI branch, prioritize BP/echo/CAC/CCTA/lipid-target review for cardiac risk, and trigger other branches only by objective persistence/recurrence. |
| **Post-Experiment Treatment-Priority Plan** | [post-experiment-treatment-priority-plan.md](topics/post-experiment-treatment-priority-plan.md) | 2026-05-03 | Result-triggered management hierarchy after the clean month: durable smoking/alcohol abstinence, BP and imaging-guided cardiovascular prevention, stool-blood/iron and CBC branches if objective signals persist, then bloating/SUDD, skin/oral inflammation, and fear-management supports. |
| **Day-0 Biomed Testing** | [planned-blood-tests.md](topics/planned-blood-tests.md) | 2026-05-04 | Completed day-0 record: insulin/glucose, reticulocyte, fibrinogen, urine, IgG/IgM, hemoglobin electrophoresis, and one concise true-SPEP caveat for IgA interpretation. |
| **Personal Knowledge-Widening Roadmap** | [personal-knowledge-widening-roadmap.md](topics/personal-knowledge-widening-roadmap.md) | 2026-05-10 | Prioritized roadmap for tests/experiments that add genuinely new personal knowledge rather than routine repeat monitoring: BP, echo, CAC/CCTA, true SPEP, triggered smear/JAK2/stool/iron branches, uACR/cystatin C, optional 24h fasting only as a gut/motility probe, and explicit low-yield parked tests. |

### CURRENT CONCERNS

| Document | File | Last Updated | Coverage |
|---|---|---|---|
| **Rebleeding Risk Analysis** | [rebleeding-risk-alcohol.md](topics/rebleeding-risk-alcohol.md) | 2026-04-25 | Alcohol gut recovery timeline, updated ferritin/iron interpretation, bloating vs rebleeding distinction, April pain episode analysis, and the new positive occult-blood context |

### PLANNING

| Document | File | Last Updated | Coverage |
|---|---|---|---|
| **Phnom Penh Medical Access** | [phnom-penh-medical-access.md](topics/phnom-penh-medical-access.md) | 2026-06-03 | Canonical local logistics with 2026-05-08 public-source rows plus 2024 RPPH historical personal bill/report evidence for right-leg arterial Doppler and hip/pelvis radiology; still covers Biomed stool/CBC/iron, RPPH coronary CT/echo/sleep/liver leads, dental leads, and Grab Mart/UCare device cautions |
| **Research Queue** | [research-queue.md](topics/research-queue.md) | 2026-05-30 | Active queue: platelet persistence / cause-attribution and reduction strategy; unified gut-symptom mechanism map across bloating, stool/spot-pain changes, bleeding/occult blood, iron shifts, CBC/inflammatory markers; focused undigested-food / mixed-consistency stool triage; CEA/tumor-marker role cleanup; and Lp(a) therapy watchlist refresh trigger. Completed/de-prioritized research ledger moved to `archive/research-queue-completed-2026-05-10.md`. |

## Active Research Queue

Active queue is now intentionally small; completed research is archived instead of carried in the active reading surface:

1. Platelet persistence / reduction strategy: why platelet counts remain borderline/high in this context, what can realistically lower them, what only lowers thrombotic risk, and when smear/molecular/hematology workup becomes the right next step.
2. Unified gut-symptom mechanism map: whether bloating, stool/spot-pain changes, bleeding/occult blood, iron shifts, and CBC/inflammatory markers share upstream drivers.
3. Undigested-food fragment and mixed-consistency stool triage: whether a one-off large pale food remnant plus mixed hard/liquid stool should change logging, motility/malabsorption interpretation, or post-experiment test triggers.
4. CEA/tumor-marker role cleanup.
5. Lp(a) therapy watchlist refresh trigger when outcomes/access status changes.

## Cross-Cutting Ownership

- [x] **Blood pressure profile** — home/ABPM acquisition protocol lives in `blood-pressure-profile.md`.
- [x] **Medication / avoid-list standardization** — current meds, aspirin rule, NSAID avoidance, PDE5/nitrate safety, and OTC analgesic defaults live in `medication-avoid-list.md`.
- [x] **Lp(a) trial watchlist** — therapy timelines and readiness logic live in `lpa-therapy-watchlist.md`.
- [x] **GI bleed + iron-loss escalation map** — positive stool-blood decision logic lives in `occult-stool-blood-workup.md`; iron interpretation lives in `ferritin-iron-workup.md`; dosing/tolerability lives in `oral-iron-repletion.md`.